A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

Oncotarget

Volumn 6, Issue 30, 2015, Pages 30408-30419

  Van Rhee, Frits ^a   Casper, Corey ^b   Voorhees, Peter M ^c   Fayad, Luis E ^d   Van de Velde, Helgi ^e   Vermeulen, Jessica ^f   Qin, Xiang ^e   Qi, Ming ^e   Tromp, Brenda ^f   Kurzrock, Razelle ^d  

^a Myeloma Institute for Research and Therapy   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f Janssen Research and Development   (Netherlands)

Author keywords

Clinical trial; Interleukin 6; Multi centric Castleman's disease; Siltuximab

Indexed keywords

SILTUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC RHINITIS; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CELLULITIS; CHRONIC OTITIS MEDIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EAR INFECTION; EYE DISEASE; FAINTNESS; FATIGUE; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFUSION RELATED REACTION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MOUTH PAIN; MULTICENTER STUDY; MULTICENTRIC CASTLEMAN DISEASE; MUSCLE SPASM; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OROPHARYNX PAIN; PERIPHERAL EDEMA; PERITONITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYCYTHEMIA; PRURITUS; PYELONEPHRITIS; RASH; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; RISK ASSESSMENT; SINUSITIS; SKIN INFECTION; THROMBOCYTOPENIA; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UREMIA; VASCULAR DISEASE; VIRUS INFECTION; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GIANT LYMPH NODE HYPERPLASIA; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84945143881     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4655     Document Type: Article

References (11)

1. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. British journal of haematology. 2005; 129:3-17.
2. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clinical advances in hematology & oncology. 2010; 8:486-498.
3. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106:2627-2632.
4. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM. The clinical spectrum of Castleman's disease. American journal of hematology. 2012; 87:997-1002.
5. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research. 2013; 19:3659-3670.
6. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, et al. Siltuximab, a novel antiinterleukin-6 monoclonal antibody, for Castleman's disease. Journal of clinical oncology. 2010; 28:3701-3708.
7. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. The lancet oncology. 2014; 15:966-974.
8. US Food and Drug Administration. FDA approves Sylvant for rare Castleman's disease. US Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm. Updated April 24 2014. Accessed April 29.
9. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014. European Medicine's Agency Web site. http://www.ema.europa.eu/ema/index.jsp?curl= pages/news_and_events/news/2014/03/news_detail_002044.jsp&mid=WC0b01ac058004d5c1 Published March 21, 2014. Accessed April 28, 2014.
10. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, Kok M, Vos K, Tas SW, Tietge UJ, Muller N, Laudes M, Gerlag DM, et al. Proatherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013; 229:174-181.
11. Actemra [prescribing information]. South San Francisco, CA: Genentech, Inc; 2014.